Compare NUVL & OLLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUVL | OLLI |
|---|---|---|
| Founded | 2017 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Department/Specialty Retail Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0B | 7.6B |
| IPO Year | 2021 | 2015 |
| Metric | NUVL | OLLI |
|---|---|---|
| Price | $100.82 | $113.70 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 13 |
| Target Price | $135.00 | ★ $140.69 |
| AVG Volume (30 Days) | 497.6K | ★ 1.0M |
| Earning Date | 02-27-2026 | 03-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.35 |
| EPS | N/A | ★ 3.61 |
| Revenue | N/A | ★ $2,537,026,000.00 |
| Revenue This Year | N/A | $19.12 |
| Revenue Next Year | N/A | $13.16 |
| P/E Ratio | ★ N/A | $31.88 |
| Revenue Growth | N/A | ★ 12.58 |
| 52 Week Low | $55.54 | $94.88 |
| 52 Week High | $113.02 | $141.74 |
| Indicator | NUVL | OLLI |
|---|---|---|
| Relative Strength Index (RSI) | 49.64 | 56.03 |
| Support Level | $98.65 | $106.52 |
| Resistance Level | $106.57 | $117.01 |
| Average True Range (ATR) | 4.46 | 3.36 |
| MACD | -0.29 | 0.74 |
| Stochastic Oscillator | 47.36 | 86.64 |
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
Ollie's Bargain Outlet Holdings Inc is a retailer of closeout merchandise and excess inventory. The company sells name brand household related items that consumers use in their everyday lives at prices that are heavily discounted below traditional retailers. It offers customers a broad selection of brand name products, including housewares, bed and bath, food, floor coverings, health and beauty aids, books and stationery, toys, and electronics. It operates stores across the Eastern half of the United States. Its differentiated go-to-market plan is characterized by a fun and engaging treasure hunt shopping experience, compelling customer value proposition, and witty, humorous in-store signage and advertising campaigns.